Clinvest

What Clinvest does

Clinvest Research is a privately held clinical research site founded in 1996 by Dr. Roger Cady in Springfield, Missouri, operating as a dedicated contract research organization (CRO) conducting FDA Phase II-IV clinical trials. The company operates as a research site within the Headlands Research network and has cumulatively completed more than 400 clinical trials (one source cites 600+) across therapeutic areas including headache and migraine, arthritis and chronic pain, diabetes and weight management, and, since 2023, vaccines (RSV, COVID, flu, pneumonia). Trials are sponsored by leading global pharmaceutical companies and are typically multi-center national or worldwide studies.

The site's core operating model is professional-services CRO delivery: physician-led study conduct, patient recruitment, data collection, and regulatory compliance, supported by a small team (11-50 employees) of board-certified principal investigators, sub-investigators, clinical research coordinators, and patient-recruitment specialists. Its proprietary asset is operational track record rather than technology; no software products, AI systems, APIs, or proprietary platforms are disclosed. Patient recruitment combines community-led outreach (open houses, Clinical Trials Day events, referral sweepstakes up to $500), healthcare-provider referrals, and direct-to-consumer website and phone intake.

Revenue flows from pharmaceutical sponsors under per-protocol research contracts; participation is free for patients, who may receive compensation for time and travel. The site has no disclosed funding events, outside equity investment, or public financials, and is privately held under the Headlands Research parent. It has contributed to FDA approvals of the Nerivio migraine-prevention device and Zepbound for chronic weight management, and is marking its 30th anniversary in 2026.

Name

Clinvest

Legal name

Clinvest Research

Website

https://clinvest.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

11–50 employees

Short description

Clinvest Research is a private Phase II-IV clinical trial site in Springfield, Missouri, founded in 1996 and operating within the Headlands Research network, conducting pharmaceutical-sponsored studies in headache, arthritis, diabetes, and vaccines.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Clinical Trial Site Operations & Study Coordination (HLAGACAE), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI)

Keywords

• Clinical research organization
• Phase II-IV trials
• Contract research services
• Clinical trial site
• Pharmaceutical research

Headquarters

HQ city

Springfield

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Clinical Research Services: Clinvest operates as a contract research organization (CRO) conducting Phase II-IV clinical trials on behalf of pharmaceutical company sponsors. They receive compensation from pharmaceutical companies for conducting trials, recruiting participants, collecting data, and ensuring regulatory compliance. Studies cover multiple therapeutic areas including headache, hypertension, diabetes, osteoarthritis, GI disorders, Alzheimer's disease, fibromyalgia, herpes simplex, asthma, low back pain, inflammatory biomarkers, and hyperlipidemia.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Clinvest Research is a clinical research organization (CRO) and dedicated clinical trial site that conducts FDA Phase II-IV studies for leading global pharmaceutical sponsors. Operating from its Springfield, Missouri facility as part of the Headlands Research network, the site recruits study participants, administers investigational treatments, collects clinical data, and ensures regulatory compliance across therapeutic areas including headache/migraine, arthritis and pain, diabetes and weight management, and vaccines.

Product overview

Clinvest Research is a dedicated clinical research organization (CRO) that conducts FDA Phase II-IV clinical trials across four therapeutic areas: Headache & Migraine Studies, Arthritis & Pain Studies, Diabetes & Weight Loss Studies, and Vaccine Studies. Founded in 1996 by Dr. Roger Cady, the company operates as a research site within the Headlands Research network. Their studies are multi-center national or worldwide trials involving hundreds to thousands of participants, led by board-certified physicians including Dr. David True (Medical Director), Dr. Ralph Duda, and Dr. Cory Bethmann. Clinvest partners with leading global pharmaceutical companies to advance medicine and bring new treatments to the world.

Differentiator

Problem solved

Functional benefit

Products and services

• Headache & Migraine Clinical Studies Clinical research trials studying migraine, tension headache, cluster headache, and migraine with aura, conducted at the Springfield, Missouri facility under board-certified physician investigators.
• Arthritis & Pain Clinical Studies Clinical trials focused on gout, fibromyalgia, psoriatic arthritis, rheumatoid arthritis, and osteoarthritis, conducted as part of multi-center national or worldwide studies sponsored by pharmaceutical companies.
• Diabetes & Weight Loss Clinical Studies Clinical research studies investigating Type 1 and Type 2 diabetes management and weight management treatments, conducted in partnership with pharmaceutical sponsors to evaluate investigational therapies.
• Vaccine Studies Clinical trials studying vaccines for RSV, COVID, flu, and pneumonia, designed to train the immune system to fight and prevent dangerous infections.

Quantifiable outcome

• Blood sugar reduction from lower 200s to mid 120s reported in diabetes trial participant testimonial

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• Headlands ResearchcoreStrategic or Co-development Partner · 1 January 1996Clinvest is a research site under Headlands Research, a network of clinical research sites. Headlands Research provides infrastructure, resources, and connection to larger multi-center clinical trials. Clinvest operates as 'A Headlands Research Site' with shared privacy policies and branding.
• Pharmaceutical CompaniescoreStrategic or Co-development Partner · 1 January 1996Clinvest partners with leading global pharmaceutical companies to conduct FDA Phase II-IV clinical trials. Studies are multi-center national or worldwide involving hundreds to thousands of participants. Sponsors include companies developing treatments for headache, diabetes, arthritis, and other conditions.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Market position

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/clinvest417
• Facebookfacebook.com/clinvestresearch
• Instagraminstagram.com/clinvest417
• LinkedInlinkedin.com/company/clinvest

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clinvest